Loading stock data…
AtaiBeckley Inc (ATAI)
$5.25-0.03 (-0.66%)
Market OpenUpdated 3:10 PM EDT
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AtaiBeckley Inc. in the Healthcare sector is trading at $5.17 with a market capitalization of $1.4B. Wall Street consensus targets $14.00 (12 analysts), implying a +171.1% move over the next 12 months. The stock is currently 23% below its 52-week high of $6.75, remaining 20.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +171.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $954,000↓ | $1.07M↑ | $749,000↑ | $719,000↓ | $1.55M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$30.16M↑ | -$39.35M↓ | -$28.41M↓ | -$25.25M↓ | -$20.34M |
| Net Income | -$29.78M↑ | -$544.81M↓ | -$61.07M↓ | -$27.73M↓ | -$26.43M |
Peer Comparison
JNJUNHPFE
Fundamentals
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation o...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.43B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-333.90%
Volume
Today's trading volume
7.27M
Recent News
AtaiBeckley to join Russell 2000 and Russell 3000 indexes following annual reconstitution
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced on Thursday that it will be added to the Russell 2000 Index and the Russell 3000 Index, effective at the open of US markets on June 29, as part of the 2026 Russell indexes reconstitution. The clinical-stage biotechnology company said the...
Why AtaiBeckley (ATAI) Is Building Its Valuation Case Around BPL-003’s Phase 3 Readiness
AtaiBeckley Inc. (NASDAQ:ATAI) is one of the small-cap stocks with potential to rise 1000 percent. The company’s investment case has become more concrete as BPL-003 moves closer to late-stage testing in treatment-resistant depression, rather than resting only on early psychedelic-drug enthusiasm. On June 8, it was reported that H.C. Wainwright reiterated a Buy rating and […]
Wall Street Bullish on AtaiBeckley (ATAI), Here’s Why
AtaiBeckley Inc. (NASDAQ:ATAI) is one of the Best Penny Stocks That Could Skyrocket in 2026. Wall Street is bullish on the stock as all 14 analysts covering the stock maintain a Buy rating, and their 12-month average price target suggests more than 280% upside from the current level. Recently, on June 8, H.C. Wainwright reiterated […]
Is AtaiBeckley Inc. (ATAI) the Hidden Penny Stock to Invest In?
AtaiBeckley Inc. (NASDAQ:ATAI) is among the hidden penny stocks to invest in. On June 8, H.C. Wainwright maintained a Buy rating on AtaiBeckley Inc. (NASDAQ:ATAI) with a price target of $25. With the highest 1-year price target among analysts, the firm’s estimate implies 561.38% upside potential. This comes after H.C. Wainwright hosted the company’s management on […]
Atai Beckley N.V. (ATAI) A Top Penny Stock to Buy Poised to Build Sustained Clinical and Shareholder Value
Atai Beckley N.V. (NASDAQ:ATAI) is one of the top penny stocks to buy in investors’ stock portfolio. On May 12, ATAI Beckley (NASDAQ:ATAI) delivered solid first-quarter results and a business update as it continues to develop its pipeline. The company remains on track to proceed with the Phase 3 Pivotal program for BPL-003, a proprietary […]